S
Shunichi Takeda
Researcher at Kyoto University
Publications - 321
Citations - 26603
Shunichi Takeda is an academic researcher from Kyoto University. The author has contributed to research in topics: DNA repair & Homologous recombination. The author has an hindex of 82, co-authored 311 publications receiving 24456 citations. Previous affiliations of Shunichi Takeda include Technische Universität Darmstadt & Osaka University.
Papers
More filters
Journal ArticleDOI
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai,Shar Yin N. Huang,Benu Brata Das,Amelie Renaud,Yiping Zhang,James H. Doroshow,Jiuping Ji,Shunichi Takeda,Yves Pommier +8 more
TL;DR: This study shows that PARP inhibitors trap the PARP1 and PARP2 enzymes at damaged DNA, providing a new mechanistic foundation for the rational application ofPARP inhibitors in cancer therapy.
Journal ArticleDOI
Homologous recombination and non‐homologous end‐joining pathways of DNA double‐strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells
Minoru Takata,Masao S. Sasaki,Eiichiro Sonoda,Ciaran G. Morrison,Mitsumasa Hashimoto,Hiroshi Utsumi,Yuko Yamaguchi-Iwai,Akira Shinohara,Shunichi Takeda +8 more
TL;DR: Observations provide the first genetic evidence that both repair pathways play a role in maintaining chromosomal DNA during the cell cycle.
Journal ArticleDOI
Rad51‐deficient vertebrate cells accumulate chromosomal breaks prior to cell death
Eiichiro Sonoda,Masao S. Sasaki,Jean-Marie Buerstedde,Olga Bezzubova,Akira Shinohara,Hideyuki Ogawa,Minoru Takata,Yuko Yamaguchi-Iwai,Shunichi Takeda +8 more
TL;DR: Chromosome analysis revealed that most metaphase‐arrested Rad51− cells carried isochromatid‐type breaks, indicating that Rad51 fulfils an essential role in the repair of spontaneously occurring chromosome breaks in proliferating cells of higher eukaryotes.
Journal ArticleDOI
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai,Shar-yin N. Huang,Amelie Renaud,Yiping Zhang,Jiuping Ji,Shunichi Takeda,Joel Morris,Beverly A. Teicher,James H. Doroshow,Yves Pommier +9 more
TL;DR: BMN 673 is the most potent clinical PARP inhibitor tested to date with the highest efficiency at trapping PARP–DNA complexes and is also approximately 100-fold more cytotoxic than olaparib and rucaparIB in combination with the DNA alkylating agents methyl methane sulfonate and temozolomide.
Journal ArticleDOI
Increased ratio of targeted to random integration after transfection of chicken B cell lines.
TL;DR: Analysis of stable transfectants revealed an unexpectedly high frequency of targeted integration into the homologous gene loci of avian leukosis virus-induced chicken B cell line DT40, which continues diversification of its rearranged light chain immunoglobulin gene by gene conversion.